Inhibition of CT-26 Murine Adenocarcinoma Growth in the Rectum of Mice Treated with Recombinant Human Interleukin-6

Micha Rabau*, Hanoch Kashtan, Shoshana Baron, Josef Yossiphov, Yehuda Skornik, Michel Revel, Avi Eisenthal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


In the present study we evaluated the antitumor effects of recombinant human interleukin-6 (rhIL-6), expressed in Chinese hamster ovary cells, in a murine primary tumor model. We showed that treatment with rhIL-6 substantially inhibited the implantation and growth rates of CT-26 adenocar-cinoma tumor cells in the rectal submucosa of syngeneic mice. This effect was achieved by injecting rhIL-6 for 7 consecutive days starting 1 day prior to tumor inoculation. No obvious antitumor effect was noted when rhIL-6 injections started 5 days after tumor inoculation. Analysis of the mechanisms by which rhIL-6 exerts its antitumor effects did not reveal a direct antitumor effect on CT-26 tumor cells or the up-regulation of major histocompatibility complex antigens on these cells. However, infiltration of lymphocytes at the tumor site was observed. Increase of carcinoembryonic antigen by IL-6 was clearly seen in human HT-29 colon carcinoma cells. The possible application of these results for adjuvant immunotherapy of selected colorectal patients and prevention of reimplantation of tumor cells disseminated during surgery is discussed.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalJournal of Immunotherapy
Issue number4
StatePublished - May 1994
Externally publishedYes


  • Carcinoembryonic antigen.
  • Colon carcinoma cells
  • Interleukin-6
  • Tumor growth and implantation


Dive into the research topics of 'Inhibition of CT-26 Murine Adenocarcinoma Growth in the Rectum of Mice Treated with Recombinant Human Interleukin-6'. Together they form a unique fingerprint.

Cite this